Patents by Inventor Tianbao Lu

Tianbao Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8076358
    Abstract: The present invention is directed to 6-substituted-thio-2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of ?-secretase, also known as ?-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: December 13, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ellen Baxter, Christopher J. Creighton, Tianbao Lu, Allen B. Reitz, Charles H. Reynolds, Tina Morgan Ross, Ellen Sieber-McMaster
  • Patent number: 8030305
    Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: October 4, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
  • Patent number: 7968725
    Abstract: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with ?-secretase activity, including Alzheimer's disease.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: June 28, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventor: Tianbao Lu
  • Patent number: 7868022
    Abstract: The present invention is directed to 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: January 11, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ellen Baxter, Allen B. Reitz, Umar Saibu Mohomed Maharoof, Yifang Huang, Christopher John Creighton, Charles H. Reynolds, Chi Luo, Brett A. Tounge, Tina Morgan Ross, Tianbao Lu
  • Patent number: 7829584
    Abstract: The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: November 9, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Tianbao Lu, Huaping Hu, Xizhen Zhu, Christopher Teleha, Kevin Kreutter
  • Patent number: 7786116
    Abstract: The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of ?-secretase, also known as ?-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: August 31, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ellen Baxter, Christopher J. Creighton, Chih Yung Ho, Yifang Huang, Tianbao Lu, Chi Luo, Allen B. Reitz, Charles H. Reynolds, Tina Morgan Ross, Ellen Sieber-McMaster
  • Patent number: 7662824
    Abstract: The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: February 16, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi Leonard, Tianbao Lu, Robert W. Tuman, Dana L. Johnson, Anna C. Maroney, Jan L. Sechler, Richard W. Connors, Richard S. Alexander, Maxwell D. Cummings, Robert A. Galemmo, Thomas P. Markotan
  • Publication number: 20100022583
    Abstract: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with ?-secretase activity, including Alzheimer's disease.
    Type: Application
    Filed: June 5, 2009
    Publication date: January 28, 2010
    Inventor: Tianbao Lu
  • Publication number: 20090227581
    Abstract: The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of ?-secretase, also known as ?-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.
    Type: Application
    Filed: January 29, 2009
    Publication date: September 10, 2009
    Inventors: Ellen Baxter, Christopher J. Creighton, Chih Yung Ho, Yifang Huang, Tianbao Lu, Chi Luo, Allen B. Reitz, Charles H. Reynolds, Tina Morgan Ross, Ellen Siber-McMaster
  • Publication number: 20090227627
    Abstract: The present invention is directed to 6-substituted-thio-2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of ?-secretase, also known as ?-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.
    Type: Application
    Filed: January 27, 2009
    Publication date: September 10, 2009
    Inventors: Ellen Baxter, Christopher J. Creighton, Tianbao Lu, Allen B. Reitz, Charles H. Reynolds, Tina Morgan Ross, Ellen Sieber-McMaster
  • Patent number: 7550474
    Abstract: Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: June 23, 2009
    Assignee: Johnson & Johnson Pharmaceuticals Research & Development, L.L.C.
    Inventors: Kevin D. Kreutter, Lily Lee, Tianbao Lu, Venkatraman Mohan, Sharmila Patel, Hui Huang, Guozhang Xu, Mark Fitzgerald
  • Publication number: 20090098181
    Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: August 7, 2008
    Publication date: April 16, 2009
    Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
  • Patent number: 7446210
    Abstract: The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
    Type: Grant
    Filed: October 24, 2005
    Date of Patent: November 4, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Tho V. Thieu, Yu-Kai Lee, Daniel J. Parks, Thomas P. Markotan, Wenxi Pan, Karen L. Milkiewicz, Mark R. Player
  • Publication number: 20080194624
    Abstract: The present invention is directed to 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of ?-secretase, also known as ?-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
    Type: Application
    Filed: February 6, 2007
    Publication date: August 14, 2008
    Inventors: Ellen Baxter, Allen B. Reitz, Umar Saibu Mohomed Maharoof, Yifang Huang, Christopher John Creighton, Charles H. Reynolds, Chi Luo, Brett A. Tounge, Tina Morgan Ross, Tianbao Lu
  • Patent number: 7402586
    Abstract: Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12—R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: July 22, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Tianbao Lu, Bruce Tomczuk, Thomas P. Markotan, Colleen Siedem
  • Publication number: 20070225282
    Abstract: The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.
    Type: Application
    Filed: March 13, 2007
    Publication date: September 27, 2007
    Inventors: Mark Player, Tianbao Lu, Huaping Hu, Xizhen Zhu, Christopher Teleha, Kevin Kreutter
  • Publication number: 20070203136
    Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: December 18, 2006
    Publication date: August 30, 2007
    Inventors: Tianbao Lu, Richard Alexander, Richard Connors, Maxwell Cummings, Robert Galemmo, Heather Rae Hufnagel, Dana Johnson, Ehab Khalil, Kristi Leonard, Thomas Markotan, Anna Maroney, Jan Sechler, Jeremy Travins, Robert Tuman
  • Patent number: 7262210
    Abstract: The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: August 28, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kevin Kreutter, Tianbao Lu, Yu Kai Lee, Christopher Teleha, Mark Player, Xizhen Zhu
  • Publication number: 20070066610
    Abstract: The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Application
    Filed: March 16, 2006
    Publication date: March 22, 2007
    Inventors: Kristi Leonard, Tianbao Lu, Robert Tuman, Dana Johnson, Anna Maroney, Jan Sechler, Richard Connors, Richard Alexander, Maxwell Cummings, Robert Galemmo, Thomas Markotan
  • Patent number: 7172742
    Abstract: The present invention relates to a method of preparing wet process phosphoric acid, which comprises: dividing raw materials which contain phosphate rock slurry and sulfuric acid into two parts, and then feeding these two parts into two reactors separately. In the first reactor, feeding 70–90 wt. % of the total amount of the slurry and sulfuric acid, in which the ratio of phosphate rock slurry to sulfuric acid to recycled phosphoric acid is set to be 1:0.6˜0.8:1.0˜2.5. 10˜30% of the reaction solution directly flows into conversion cell, participating in the conversion reaction of dihydrate gypsum. Thus resulted phosphoric acid concentration is 33˜39 wt. %. The recovery efficiency of P2O5 is 99% or more. When putting coke powders in the conversion solution as filter aid, the filtration efficiency can be improved by 10˜30%, and in so produced hemihydrate gypsum, P2O5 is 0.05˜0.2%, water of hydration is 4˜8%. The product can be used for producing sulfuric acid and cement without baking dry.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: February 6, 2007
    Assignee: Shandong Lubei Enterprise Group Company
    Inventors: Yisheng Feng, Jiutian Feng, Xigang Liu, Yurui Wang, Tianbao Lu